30 yrs

Choose your Category
of Interest


catalog download









Access Technologies 2016 Product Catalog
Download now

Request a copy by mail



tcs vial


TCS Catheter Lock Solution

....an Anti-Microbial Lock Solution providing patency and infection control

....a revolutionary approach to catheter maintenance



The Researchers New Best Friend



pdf Download our TCS product information sheet


pdf New to TCS





  • Components
  • Advantages
  • Bibliography

TCS combines two active ingredients vital to the effective management of vascular access catheters - Taurolidine and Citrate. When catheters are locked with TCS, their internal flow passages are resistant to clot formation and hostile to bacterial and fungal growth.



- chemically modified amino acid taurine

- interacts with components of microbial cell walls, resulting in irreparable injury

- prevents intraluminal microbial colonization
- inhibits biofilm that can allow protected microbial colonization
- acts effectively against a broad range of bacteria and fungi
- does not induce development of resisitant microbes



- anticoagulant component of TCS

- forms a complex with calcium in the blood, disrupting the normal coagulation cascade
- inhibits intraluminal blood coagulation with no systemic effect


Prevention of catheter related infection Taurolidine has broad spectrum antimicrobial activity against gram-positive and gram-negative bacteria, yeast and fungi
Reduced risk of biofilm formation Taurolidine causes a loss of microbial fimbriae and flagellae, altering the microbial surface, preventing colonization
Supports catheter patency The citrate ion chelates calcium ions in the blood by forming calcium citrate complexes, disrupting the clotting mechanism.
No development of resistance Due to the mode of action of Taurolidine directly on microbial cell walls, development of resistance is unlikely
(in contrast to the development of resistance to antibiotics)
Favorable safety profile No systemic nor toxic effects of Taurolidine have been identified. Its' safety has been confirmed in clinical studies with long term intravenous administration of high doses


email us Email if you have any questions about TCS


Betjes M. et. al. "Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution". 2004


Koldenhoff M. et. al. "Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients". 2004


Jurewitsch B .et. al. "Taurolidine Lock: the key to prevention of recurrent catheter-related bloodstream infections". 2005


Mandolfo S. et. al. "Catheter lock solutions:it's time for a change." 2006


Bradshaw JH. et. al. "Taurolidine and catheter related bloodstream Infection: A systematic review of the literature". 2008


Simon A. et. al. "Taurolidine-citrate lock solution significantly reduces CVAD-associated gram-positive infections in pediatric cancer patients". 2008




email us Email for copy of article(s) you are interesting in reading














made in the usa